The HH/B‑DM4‑NT platform integrates bacterial collagenolysis, ligand‑guided targeting, cytoskeleton disruption, and sonodynamic immunotherapy. HH bacteria degrade ECM via collagenases; surface NT ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks. For people with non-muscle invasive bladder cancer ...
Intrauterine devices (IUDs), also known as coils, are safe and effective contraceptive methods. According to representative surveys conducted by the Federal Centre for Health Education (BZgA) in ...
The European Society of Cardiology (ESC) publishes clinical practice guidelines and related resources to support everyone involved in cardiovascular care. Grounded in the latest evidence, these ...
The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in patients with carcinoma in situ. The Food and Drug Administration (FDA) ...
Before the launch of this health guide, the publisher promised a fanfare of publicity that would have outdone memoirs from presidents and Nobel Prize winners. This was muted in Europe, which is a pity ...
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning. On October 14, 2026, the ...
The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience/ ImmunityBio), in combination with bacillus Calmette-Guérin (BCG), for adults with BCG-unresponsive non-muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results